×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
UMass Chan licenses gene therapy technologies for retinal diseases to Iveric Bio
UMass Chan Medical School
UMass Chan licensed the exclusive global rights to develop and commercialize novel adeno-associated virus gene therapy product candidates...
2 months ago
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic ...
PR Newswire
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA).
7 months ago
Astellas Pharma buys Iveric Bio for $5.9 billion
Reuters
Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition,...
11 months ago
Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy
Ophthalmology Times
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA...
8 months ago
Eric Stonestreet teams with Iveric Bio for eye disease campaign
Fierce Pharma
Iveric Bio has launched a new awareness campaign featuring actor Eric Stonestreet for a disease it recently received FDA approval to treat.
7 months ago
Iveric Bio reports positive data from GA therapy trial
Clinical Trials Arena
Astellas company Iveric Bio has reported positive two-year-data from the Phase III GATHER2 clinical trial of IZERVAY.
7 months ago
Iveric Gets FDA Approval in Geographic Atrophy After Being Acquired by Astellas
BioSpace
Friday, Iveric Bio scored a regulatory win for its geographic atrophy eye injection Izervay, just three months after the New Jersey biotech...
8 months ago
Iveric Bio's intravitreal solution to treat GA receives FDA approval
Pharmaceutical Technology
Iveric Bio's intravitreal solution to treat GA gains FDA approval. A statistically significant reduction in the rate of GA progression at 12...
8 months ago
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol ...
ABC27
GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.
7 months ago
Geographic Atrophy Market Anticipated Growth by 2032, as Predicted by DelveInsight | Apellis Pharmaceuticals, Iveric ...
Barchart.com
"Geographic Atrophy Market"Geographic Atrophy companies are Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation),...
1 week ago